LLYELI LILLY & Co

NYSE lilly.com


$ 770.01 $ -1.11 (-0.14 %)    

Friday, 17-May-2024 15:59:57 EDT
QQQ $ 451.45 $ -1.25 (-0.28 %)
DIA $ 399.76 $ 0.64 (0.16 %)
SPY $ 529.26 $ 0.18 (0.03 %)
TLT $ 91.40 $ -0.22 (-0.24 %)
GLD $ 223.63 $ 1.39 (0.63 %)
$ 771.12
$ 771.93
$ 0.00 x 0
$ 0.00 x 0
$ 767.65 - $ 774.74
$ 416.69 - $ 799.42
2,299,653
na
696.94B
$ 0.57
$ 113.54
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eli-lillys-weekly-insulin-dose-on-par-with-commonly-used-daily-doses-phase-3-studies-show

Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 d...

 eli-lillys-qwint-2-and-qwint-4-phase-3-trials-of-once-weekly-insulin-efsitora-in-type-2-diabetes-patients-using-insulin-for-first-time-and-require-multiple-daily-injections-efsitora-showed-non-inferior-a1c-reduction-vs-most-commonly-used-daily-insulin

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 d...

 no-wegovy-shortage-in-denmark-amid-high-demand-novo-nordisk-confirms

Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines A...

 eli-lilly-strikes-deal-to-combat-counterfeit-diabetes-and-weight-loss-drugs-mounjaro-and-zepbound

Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease us...

Core News & Articles

https://www.wsj.com/livecoverage/stock-market-today-dow-jones-05-14-2024/card/lilly-settles-with-spa-selling-mounjaro-zepbound-...

 argus-research-maintains-buy-on-eli-lilly-and-co-raises-price-target-to-840

Argus Research analyst David Toung maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $770 to...

 pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients

Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID ...

 google-deepmind-develops-latest-ai-model-to-aid-scientists-in-fighting-disease

Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.

 hedge-fund-legend-druckenmiller-shares-his-top-secrets-for-30-returns

Legendary hedge fund manager Stanley Druckenmiller made right bets at the right time. He came to fame for earning Soros $10B ov...

 what-about-eli-lillys-drug-for-early-alzheimers-fda-panel-to-discuss-next-month

FDA's advisory committee meeting on June 10, 2024, discussing Eli Lilly's donanemab for early Alzheimer's.

 eli-lilly-says-fda-to-convene-in-person-meeting-of-peripheral--central-nervous-system-drugs-advisory-committee-on-june-10-to-discuss-donanemab

-Reuters

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION